삼성바이오로직스

At Samsung Biologics, we offer agile and flexible development services to meet your evolving needs. Click here to schedule a meeting with our CDO experts and develop a plan that prioritizes your specific requirements. https://lnkd.in/gUKzqtv8  #SamsungBiologics #CDO #Agile #Flexible #FocusedOnYou

Establishing an effective chemistry, manufacturing, and control (CMC) strategy is critical to ensure the safety and quality of drug products. In this article, our analytical scientists discuss how we develop tailored strategies to support the development of next-generation biologics. Read more: https://lnkd.in/gtBfz_Yr #SamsungBiologics #cdmo #CMC #drugdevelopment 

We’re attending the mRNA-Based Therapeutics Summit in Boston between July 29-31! Join our speaking session on July 30 at 2:45 PM (ET), where Eunseo Lee, our Lead Engineer in mRNA manufacturing, will present on key considerations for analytical characterization. You can also drop by booth #42 to learn about our capabilities and how we can support your mRNA goals. #SamsungBiologics #cdmo #mRNA #manufacturing 

We sincerely thank everyone who connected with us at BIOPLUS-INTERPHEX Korea 2024. We hope for continued discussions that can lead to collaboration opportunities going forward. Check out some highlights from the event. #SamsungBiologics #BIOPLUSINTERPHEX_Korea #CDMO #Biopharma #Partnership

As innovative treatments require stringent quality control measures, drug manufacturers are increasingly embracing Quality by Design (QbD) as a pivotal strategy. In this article, Songyoung Kim, Director of CDO Downstream and Development, discusses how QbD effectively addresses potential variability and risks, thereby optimizing processes and ensuring successful development outcomes. Read here: https://lnkd.in/g_ZfRRRe #SamsungBiologics #drugdevelopment #QbD #cdmo

Are you attending BIOPLUS-INTERPHEX Korea? Visit booth #M21 to learn about our innovative technologies and capacity and portfolio expansion plans. We also have a speaking session on July 11 at 10:20 AM (KST), where Heonchang Lim, Director of Formulation Development, will share insights on reducing candidate risk and achieving development success using our developability assessment tool, DEVELOPICK™. #SamsungBiologics #networking #BIOPLUS_INTERPHEXKorea

Due to the complexities of biologics development, a CDMO partner that has the capacity and expertise to support the entire drug journey is crucial for success. In this webinar, Thomas Rohrer, Senior Director of Bioconjugate Technology Support, highlights our comprehensive service offerings as well as expansion in the ADC space. Watch it on demand! https://lnkd.in/gwn28WRc #SamsungBiologics #cdmo #partner #biopharma

Our dedicated, standalone antibody-drug conjugate (ADC) facility is on track for completion within this year. Located across from both Bio Campus I and II, the facility will enable us to offer seamless services from development to manufacturing for your ADC project. Stay tuned for additional updates as we advance to provide innovative therapeutics. https://lnkd.in/gE-aCSMV #SamsungBiologics #ADC #biomanufacturing #innovation

We’re excited to participate in BIOPLUS-INTERPHEX Korea! Join us for our speaking session on July 11 at 10:20AM (KST), where Heonchang Lim Director of Formulation Development, will present on our robust developability assessment tool, DEVELOPICK™. Our team will also be available at booth #M21 to discuss collaboration opportunities. #SamsungBiologics #networking #BIOPLUS-INTERPHEXKorea

Mark your calendar for the mRNA-Based Therapeutics Summit in July! We’re excited to connect with industry experts and discuss the future of mRNA technologies. Stop by booth #42 to learn about our service scope and capabilities. https://lnkd.in/g5FwenV #SamsungBiologics #mRNAtherapeutics #innovation #networking #partnership